Fuzeon needle-free sNDA not trouble-free
This article was originally published in Pharmaceutical Approvals Monthly
Roche and Trimeris expect their response to a November 2005 "approvable" letter for needle-free administration of the HIV fusion inhibitor Fuzeon (enfuvirtide) "will be delayed until at least the first half of 2007," the companies announce Oct. 11. The sponsors had originally projected a second-half 2006 resubmission of the sNDA, which seeks to add information to labeling regarding Fuzeon's use with the Biojector 2000 device (1Pharmaceutical Approvals Monthly February 2006, p. 17). While FDA acknowledged in recent discussions that bioavailability was comparable between conventional Fuzeon and the needle-free delivery method, Roche/Trimeris said the agency expressed concern about hematomas and nerve pain seen with the Biojector device. As a result, FDA is requesting additional safety information, including data from the Fuzeon BOSS trial (Biojector Open Label Safety Study)...
You may also be interested in...
Trimeris expects to submit a response to FDA in the second half of 2006 following receipt of an "approvable" letter for use of its fusion inhibitor Fuzeon with a needle-free injection system
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.